Loading company
Just reported
Q3 2026 results
From Maze Therapeutics's results release of November 9, 2026; its quarterly report has since been filed.
Revenue
Actual
$0.00
Guided
—
No guide given
EPS, GAAP
Actual
-$0.79
Guided
—
No guide given
Operating income, GAAP
Actual
-$51.5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Maze Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$48BA+
EXELExelixis, Inc.$17.3BA+
JAZZJazz Pharmaceuticals plc$15.9BA
HALOHalozyme Therapeutics, Inc.$11.6BA+
TECHBIO-Techne Corp$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now A
How it makes money
- Licensing and collaboration payments
Competes with
What it sells6
MZE829
An oral drug candidate designed to block APOL1, a protein linked to kidney damage in some people with inherited APOL1 gene variants. It is being tested in people with APOL1-related kidney disease.
MZE782
An oral drug candidate that blocks a transporter involved in moving amino acids through the gut and kidneys. It is being studied for PKU and is also being developed for chronic kidney disease.
MZE001
An oral drug candidate designed to reduce glycogen buildup in muscle in people with Pompe disease. Maze licensed it to Shionogi, which is developing it.
Show 3 more
ATXN2 program
A gene therapy program designed to lower production of the ATXN2 gene product, which Maze studied as a possible approach to amyotrophic lateral sclerosis. Maze licensed the program to Neurocrine Biosciences.
UNC13A program
A drug research program based on the UNC13A gene and its link to amyotrophic lateral sclerosis and frontotemporal dementia. Maze licensed the program to Trace Neuroscience.
ANGPTL7 program
A research program for antibody drugs targeting ANGPTL7, a gene linked to eye pressure and glaucoma. The program is being developed by Broadwing, a company Maze formed with Alloy Therapeutics.
Who buys it3
- Shionogi licenses MZE001 and pays Maze development and sales milestone payments, plus royalties if the drug is sold.
- Neurocrine Biosciences licensed Maze's ATXN2 program and may pay development, regulatory, and sales milestones and royalties.
- Trace Neuroscience licensed Maze's UNC13A program and may pay development, regulatory, and sales milestones and royalties.
What it stands on, and what could break it
What the business leans on
- 1Maze relies on outside companies to run clinical trials and manufacture drug supplies for its studies.
- 2Its genetic research depends on access to genetic data paired with health information, including data accessed through agreements with the University of Helsinki.
- 3Maze has no product sales and relies on financing and licensing payments to fund research and drug development.
- 4Revenue from licensed drug programs depends on partners continuing development and reaching payment milestones or selling products.
What could go wrong
- 1The drug candidates are still being tested; results from small or early studies may not predict whether later studies will show safety and benefit.
- 2Delays or problems at outside clinical-trial or manufacturing providers could interrupt studies or limit the supply of drugs for trials.
- 3Maze has no product sales and expects continued research and trial costs, so it may need more financing; if funding is unavailable, it may have to delay or reduce development work.
About Maze Therapeutics, Inc.
Maze uses human genetic and health data to find gene changes linked to disease and to identify drug targets. Its main drug candidates are designed for chronic kidney disease (CKD), including kidney disease linked to apolipoprotein L1 (APOL1), and phenylketonuria (PKU), an inherited disorder that causes harmful levels of an amino acid to build up. Maze also licenses some drug programs to other drug companies.
- Head office
- South San Francisco, California
- Founded
- 2018
- Listed on
- Nasdaq
- Financial year ends
- December 31
Built from Maze Therapeutics, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
